1532 - Expansion of genetic testing for myeloproliferative neoplasms under MBS item 73325

Page last updated: 21 September 2020

Application Detail

Description of Medical Service

Molecular testing for the diagnosis of polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF) can establish the presence or absence of specific mutations known to occur in patients with these disorders. MBS item 73325 currently provides for Janus kinase (JAK2) and myeloproliferative leukaemia (MPL) gene testing in patients with PV or ET. The proposed medical service being requested is the expansion of MBS item 73325 to allow testing for calreticulin (CALR) mutations in patients with PV or ET, and testing for JAK2, MPL and CALR genes in patients with primary myelofibrosis (PMF).

Description of Medical Condition

Myeloproliferative neoplasms (MPNs) are a group of disorders in which bone marrow stem cells grow and reproduce abnormally. PV, ET and PMF are MPN's.

Reason for Application

-

Medical Service Type

Investigative

Previous Application Number

1125

Associated Documentation

Application Form

-

Consultation Survey

-

PICO Confirmation

-

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 945 KB)
Public Summary Document (Word 216 KB)

Meetings for this Application

PASC

-

ESC

8 February 2019
8-9 October 2020

MSAC

28-29 March 2019